Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200048/S001

IsoPSA Assay

Cleveland Diagnostics, Inc. · Decision date Jul 28, 2026

FDA DECISIONP200048/S001

What did the FDA approve?

FDA records P200048/S001 as a supplement to PMA P200048, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 28, 2026.

FDA approval order statement

extension of the shelf-life of the IsoPSA Controls
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Immunology
Decision date
Jul 28, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P200048/S001
Regulatory pathway
PMA supplement
Product code
QRF
Decision code
APPR
Decision date
Jul 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-analyte test system with algorithmic analysis for detection of prostate cancer.

Product code
QRF
FDA device class
3

For the original device and its historical approval scope, see PMA P200048. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P200048/S001 received

    Application receipt date recorded by FDA.

  2. P200048/S001 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P200048. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200048

Product / regulatory recordCompanyPathwayDecision dateSource
Cleveland Diagnostics, Inc.PMA approvalNov 28, 2025FDA

Explore the linked device profile

Other records with product code QRF

Product / regulatory recordCompanyPathwayDecision dateSource
4Kscore TestP190022/S003
Opko Health, Inc.PMA supplementJul 25, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cleveland Diagnostics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3615 Superior Ave., Suite 4407b, Cleveland, OH, 44114

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records